Our center for wellness, The Longevity Center or TLC has been promoting IV or intravenous EDTA chelation therapy since 2010. Our 10 years of experience in providing this Integrative Medicine therapy made an impact in the lives of hundreds of patients, supporting our goal to “add more years to life, and add life to years”. This is the motto of most wellness centers promoting longevity, health and wellness. As we embark into our second decade of being preventative health care providers, we aim “To bring Integrative Medicine into the lives of more. “
Some of the following questions and answers were copied directly from site of The Magaziner Center for Wellness, a testing site for the ongoing TACT (Trial to Assess Chelation Therapy) 2 study in the US.
What is Chelation?
Chelation involves the intravenous infusion of vitamins, magnesium and a chelating agent known as EDTA (specifically disodium EDTA). This IV infusion “chelates,” or captures toxic heavy metals floating in the blood and the calcium and free radicals that can bind to the blood vessel walls. These harmful compounds are then excreted in the urine.
The goal of the treatment is to make the blood vessels more pliable, improve blood circulation, and reduce or eliminate chest pain and other symptoms of cardiovascular disease. Patients who have completed a course of chelation therapy often notice an improvement in their energy and well-being, and are often able to reduce or eliminate their need for medication.
Why explore Chelation?
Doctors at the Columbia University Division of Cardiology, at Mount Sinai Medical Center in Miami Beach, provide an introduction to chelation therapy in their paper published in the journal: Trends in Cardiovascular Medicine.(1)
“Medical practitioners have treated atherosclerotic disease (the buildup of plaque in arteries) with chelation therapy for some 60 years. Lack of strong evidence led conventional practitioners to abandon its use in the 1960s and 1970s. This relegated chelation therapy to complementary and alternative medicine practitioners, who reported good anecdotal results.
Concurrently, the epidemiologic evidence (evidence that Chelation Therapy can control cardiovascular disease) linking xenobiotic (synthetic, toxic) metals with cardiovascular disease and mortality gradually accumulated, suggesting a plausible role for chelation therapy. On the basis of the continued use of chelation therapy without an evidence base, the National Institutes of Health released a Request for Applications for a definitive trial of chelation therapy. The Trial to Assess Chelation Therapy (TACT) was formulated.”
What are the TACT and TACT2 Chelation clinical trials?
To explain this program, the following is a summary of information from the Questions and Answers: The NIH Trials of EDTA Chelation Therapy for Coronary Heart Disease page at the National Center for Complementary and Integrative Health (NCCIH). Part of the the United States National Institutes of Health (NIH).
TACT was the first large-scale, multicenter study designed to determine the safety and efficacy of EDTA chelation therapy for individuals with prior heart attacks.
The goal of the study was to determine the safety and efficacy of EDTA chelation therapy for treating coronary heart disease. TACT was designed to see whether EDTA chelation therapy and/or high-dose vitamin/mineral supplements are safe and effective in treating individuals with prior heart attacks. Specifically, they sought to determine if EDTA chelation and/or high-dose vitamin supplements improved event-free survival (length of time without a cardiovascular event, such as a heart attack) in participants who were also treated with the gold standard approach (traditional coronary heart disease care) for their cardiovascular disease.
What were the key results of the study?
TACT provides evidence that a regimen of 40 infusions of disodium EDTA modestly reduced the risk of some cardiac events in adults who had previously had a heart attack. This treatment effect lasted over the 5-year follow-up period.
Overall, those receiving chelation had an 18% reduced risk of subsequent cardiac events such as heart attack, stroke, hospitalization for angina, or coronary revascularization. A cardiac event occurred in 222 (26%) of the chelation group and 261 (30%) of the placebo group.
These results are not, by themselves, sufficient to support the routine use of chelation as post-heart attack therapy.
The researchers compared the results for people who did or did not have diabetes. People with diabetes made up 37% of the total group. The researchers found that:
Among patients with diabetes, those receiving chelation had a lower risk of cardiovascular events such as heart attack, stroke, hospitalization for angina, or coronary revascularization.
Events occurred in 25% of the patients with diabetes who received EDTA chelation and in 38% of those who received placebo. Death from any cause was 43% lower in those patients with diabetes who received chelation.
Among patients who did not have diabetes, chelation therapy was not associated with a reduction in cardiovascular events. These results are not, by themselves, sufficient to support the routine use of chelation as post-heart attack therapy in people with diabetes.
“Because of the generic nature of this intervention, there is absolutely no pharmaceutical company interest in this therapy, so all of us await NIH initiatives”
In the conclusion of the research paper cited above (1) the investigators lead by Gervasio A. Lamas, MD commented on these results:
“At present, the unique nature of these findings demands follow-up research to replicate findings and understand mechanisms. . . Because of the generic nature of this intervention, there is absolutely no pharmaceutical company interest in this therapy, so all of us await NIH initiatives. Still, the magnitude of benefit was such that it suggests urgency in replication and implementation, which should, due the excellent safety record, occur simultaneously.”
TACT2 is a current and ongoing clinical trial. It repeats the first TACT study but is limited to patients with diabetes and a prior heart attack history. The goal of the study is to determine if the apparent benefit of EDTA chelation therapy published in the first TACT study, in this select group of patients, can be confirmed.
References provided by The Magaziner Center for Wellness for their article as follows:
1 Peguero JG, Arenas I, Lamas GA. Chelation therapy and cardiovascular disease: connecting scientific silos to benefit cardiac patients.Trends Cardiovasc Med. 2014 Aug;24(6):232-40. doi: 10.1016/j.tcm.2014.06.002. Epub 2014 Jun 12.
2 Peguero JG, Arenas I, Lamas GA. Chelation therapy and cardiovascular disease: connecting scientific silos to benefit cardiac patients. Trends Cardiovasc Med. 2014 Aug;24(6):232-40. doi: 10.1016/j.tcm.2014.06.002. Epub 2014 Jun 12. PMID: 25106084; PMCID: PMC4152775.
At present, due to the ongoing pandemic, minimum health standards and social distancing measures are being implemented and followed strictly in our Center. Please cooperate and abide with our rules. If interested in our therapies, please connect with us before coming to our clinic for a visit or consultation via our Facebook page (Messenger): The Longevity Center Chelation and Wellness Clinic, Inc. Please do not message through this website as it is not visited regularly by Admin. You can also send an email inquiry to: email@example.com.
We are strictly on a BY APPOINTMENT basis only. No WALK INS. Maximum of 3 patients per timeslot with 3 timeslots/day only. Timeslots for therapy and consultations are 9 AM, 12 NN and 3 PM.
You can also contact us through our official numbers:
Landlines: (0063-2) 8373116334117391; Cellphone# (0063) 9258411088
By: Dr. Glorybelle Molano, Lead Physician, The Longevity Center Chelation and Wellness Clinic, Inc.